The clinical data of 160 cases of acute ischemic stroke patients were analyzed retrospectively.The patients were divided into control group（non-CMBs group，n=39） and CMBs group（n=116） acording to the head checking results detected by magnetic sensitive weighted imaging （SWI）.The patients in CMBs group were then divided into 3 subgroups： low-risk group， middle-risk group and high-risk group according to CMBs severity score—NSL score.The patients in various groups were given conventional treatment after admission， based on which they were given dual anti-platelet therapy， aspirin 100 mg orally once a day and clopidogrel 75 mg orally once a day for 21 d according to the Stroke Guidelines 2018， after which aspirin 100 mg once a day or clopidogrel 75 mg once a day was given as the monotherapy， and no other anticoagulant or antiplatelet drugs were given during the treatment period. CT and SWI examination of the head and the neurological deficit score according to the National Institute of Health Stroke Scale （NIHSS） were performed at admission. The CT of head and NIHSS scores were rechecked after 21 d of dual anti-treatment， and the number of bleeding regression cases was counted. The neurological recovery statuses of the patients in various groups were detected by modified Rankin Scale（mRS） score after 21 d， 3 months and 6 months of dual anti-treatment.

There were no significant differences in the conversion rates of cerebral hemorrhage，NIHSS scores and mRS scores of the patients after dual anti-platelet therapy between control group and CMBs group （P>0.05）； compared with control group， the conversion rates of cerebral hemorrhage， NIHSS scores and mRS scores of the patients in low-risk group and middle-risk group in CMBs group had no significant differences（P>0.05），the conversion rate of cerebral hemorrhage of the patients in high-risk group was increased（P<0.05），but there were no significant differences in the NIHSS scores and mRS scores of the patients between high-risk group and control group （P>0.05）.

The application of dual anti-platelet therapy does not increase the risk of intracranial hemorrhage， nor does it affect the neurological recovery or long-term prognosis in the acute ischemic stroke patients complicated with low-risk and middle-risk CMBs； the acute ischemic stroke patients complicated with high-risk CMBs have the risk of bleeding regression.